Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855177 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02855177 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT02855177, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG PF-06427878
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2017-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855177
The ClinicalTrials.gov registry entry for NCT02855177 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02855177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855177 about?
NCT02855177 is a clinical study titled "A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects". PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.
What is the current status of trial NCT02855177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-08-24. Estimated completion is 2017-04-12.
What interventions are being tested in trial NCT02855177?
The interventions under investigation include: Placebo (DRUG), PF-06427878 (DRUG).
Who is sponsoring clinical trial NCT02855177?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.